Phase II Study of Weekly Paclitaxel (BMS-181339)in Patients With Advanced or Recurrent Esophageal Cancer

Bristol-Myers Squibb53 enrolled

Overview

The purpose of this clinical research study is to learn if BMS-181339 can shrink or slow the growth of the cancer in patients with advanced or recurrent esophageal cancer. The safety of this treatment will also be studied.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Esophageal Cancer

Interventions

PaclitaxelDRUG

Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must have measurable disease * Patients must have experienced on pervious chemotherapy regime * Men and Women, with the age 20 years or older * ECOG PS: 0-1 Exclusion Criteria: * Patients with previous therapy with Taxanes

Locations (12)

Local Institution

Nagoya, Aichi-ken, Japan

Local Institution

Kashiwa-Shi, Chiba, Japan

Local Institution

Sagamihara-Shi, Kanagawa, Japan

Local Institution

Outcomes

Primary Outcomes

Overall response rate

Time frame: at the end of the study

Safety

Time frame: at the end of the study

Secondary Outcomes

Response duration

Time frame: at the end of the study

Time to progression (TTP)

Time frame: at the end of the study

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.